RT Journal Article
SR Electronic
T1 Activated NK Cells with Pro-inflammatory Features are Associated with Atherogenesis in Perinatally HIV-Acquired Adolescents
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.06.23297580
DO 10.1101/2023.11.06.23297580
A1 Alles, Mario
A1 Gunasena, Manuja
A1 Kettelhut, Aaren
A1 Ailstock, Kate
A1 Musiime, Victor
A1 Kityo, Cissy
A1 Richardson, Brian
A1 Mulhern, Will
A1 Tamilselvan, Banumathi
A1 Rubsamen, Michael
A1 Kasturiratna, Dhanuja
A1 Demberg, Thorsten
A1 Cameron, Cheryl M.
A1 Cameron, Mark J.
A1 Dirajlal-Fargo, Sahera
A1 Funderburg, Nicholas T.
A1 Liyanage, Namal P.M.
YR 2023
UL http://medrxiv.org/content/early/2023/11/07/2023.11.06.23297580.abstract
AB Human immunodeficiency virus (HIV) is associated with persistent immune activation and dysfunction in people with HIV despite treatment with antiretroviral therapy (ART). Modulation of the immune system may be driven by: low-level HIV replication, co-pathogens, gut dysbiosis /translocation, altered lipid profiles, and ART toxicities. In addition, perinatally acquired HIV (PHIV) and lifelong ART may alter the development and function of the immune system. Our preliminary data and published literature suggest reprogramming innate immune cells may accelerate aging and increase the risk for future end-organ complications, including cardiovascular disease (CVD). The exact mechanisms, however, are currently unknown. Natural killer (NK) cells are a highly heterogeneous cell population with divergent functions. They play a critical role in HIV transmission and disease progression in adults. Recent studies suggest the important role of NK cells in CVDs; however, little is known about NK cells and their role in HIV-associated cardiovascular risk in PHIV adolescents. Here, we investigated NK cell subsets and their potential role in atherogenesis in PHIV adolescents compared to HIV-negative adolescents in Uganda. Our data suggest, for the first time, that activated NK subsets in PHIV adolescents may contribute to atherogenesis by promoting plasma oxidized low-density lipoprotein (Ox-LDL) uptake by vascular macrophages.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health (NIH/NIAID) grant U01 AI168630-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained approval by the Research Ethics Committee in Uganda, University Hospitals Cleveland Medical Center, Cleveland, Ohio and The Ohio State University. Caregivers gave written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes